Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) FCF Margin: 2019-2025

Historic FCF Margin for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to 21.86%.

  • Keros Therapeutics' FCF Margin rose 798216.00% to 21.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.30%, marking a year-over-year increase of 2192516.00%. This contributed to the annual value of -4,585.92% for FY2024, which is 7950150.00% up from last year.
  • As of Q3 2025, Keros Therapeutics' FCF Margin stood at 21.86%, which was up 113.09% from -167.01% recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' FCF Margin peaked at 1,814,700.00% during Q2 2021, and registered a low of -431,650.00% during Q3 2023.
  • For the 3-year period, Keros Therapeutics' FCF Margin averaged around -69,179.76%, with its median value being -7,960.31% (2024).
  • In the last 5 years, Keros Therapeutics' FCF Margin surged by 91,430,000bps in 2021 and then slumped by 107,150,874bps in 2022.
  • Keros Therapeutics' FCF Margin (Quarterly) stood at -98.62% in 2021, then plummeted by 107,150,874bps to -8.74% in 2022, then reached -18,181.82% in 2023, then soared by 1,665,989bps to -1,521.93% in 2024, then surged by 798,216bps to 21.86% in 2025.
  • Its last three reported values are 21.86% in Q3 2025, -167.01% for Q2 2025, and 76.03% during Q1 2025.